Résumés
Résumé
Un gain de poids significatif est associé à l’utilisation des antipsychotiques atypiques, des stabilisateurs de l’humeur et des antidépresseurs employés seuls ou en combinaison. Les personnes avec des troubles psychiatriques sont plus à risque de souffrir d’obésité et du syndrome métabolique que la population générale. Une approche prometteuse pour limiter les conséquences physiques et psychologiques du gain de poids est la modification des habitudes de vie. Nous avons révisé la littérature afin de détailler l’impact de ces programmes sur différentes mesures d’effet. Douze des dix-sept études recensées rapportent un impact significatif de leur programme sur le poids en comparaison des soins usuels généralement offerts aux personnes avec des troubles psychiatriques. L’importance de la mise en place de ces programmes pour les patients psychiatriques en externe est soulignée.
Mots-clés :
- troubles de l’humeur,
- schizophrénie,
- gain de poids,
- obésité,
- intervention non-pharmacologiques,
- qualité de vie
Abstract
Significant weight gain is common in patients with psychiatric disorders taking antipsychotics, mood stabilisers and/or antidepressants. Psychiatric patients are at a higher risk of suffering from obesity and from the metabolic syndrome than the general population. One promising alternative to limiting weight gain involves modifying lifestyle behaviors. We reviewed the literature on behavioral weight management programs for this clientele. Of the 17 identified studies, 12 reported a significant impact of the program on weight gain compared to usual care. The importance of offering weight management programs to psychiatric patients in outpatient settings is stressed.
Keywords:
- mood disorders,
- schizophrenia,
- weight gain,
- obesity,
- non-pharmacological interventions,
- quality of life
Parties annexes
Bibliographie
- ADULT TREATMENT PANEL III, 2001, Executive summary of the third report of the National Cholesterol Education Program (NCEP), Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III), Journal of the American Medical Association, 285, 19, 2486-2497.
- ALLISON, D. B., MACKELL, J. A., MCDONNELL, D. D., 2003, The impact of weight gain on quality of life among persons with schizophrenia, Psychiatric Services, 54, 4, 565-567.
- ÁLVAREZ-JIMÉNEZ, M., GONZÁLEZ-BLANCH, C., VÁZQUEZ-BARQUERO, J. L., PÉREZ-IGLESIAS, R., MARTÍNEZ-GARCÍA, O., PÉREZ-PARDAL, T., CRESPO-FACORRO, B., 2006, Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients : A randomized controlled trial, Journal of Clinical Psychiatry, 67, 8, 1253-1260.
- ÁLVAREZ-JIMÉNEZ, M., HETRICK, S. E., GONZÁLEZ-BLANCH, C., GLEESON, J. F., MCGORRY, P. D., 2008, Non-pharmacological management of antipsychotic-induced weight gain : Systematic review and meta-analysis of randomised controlled trials, British Journal of Psychiatry, 193, 2, 101-107.
- ANDERSON, J. W., KONZ, E. C., FREDERICH, R. C., WOOD, C. L., 2001, Long-term weight-loss maintenance : A meta-analysis of US studies, The American Journal of Clinical Nutrition, 74, 5, 579-584.
- ARONNE, L. J., SEGAL, K. R., 2003, Weight gain in the treatment of mood disorders, Journal of Clinical Psychiatry, 64, Suppl. 8, 22-29.
- ATMACA, M., KULOGLU, M., TEZCAN, E., USTUNDAG, B., 2003, Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain, Human Psychopharmacology : Clinical and Experimental, 18, 6, 457-461.
- ATMACA, M., KULOGLU, M., TEZCAN, E., USTUNDAG, B., KILIC, N., 2004, Nizatidine for the treatment of patients with quetiapine-induced weight gain, Human Psychopharmacology : Clinical and Experimental, 19, 1, 37-40.
- BALL, M. P., COONS, V. B., BUCHANAN, R. W., 2001, A program for treating olanzapine-related weight gain, Psychiatric Services, 52, 7, 967-969.
- BRAR, J. S., GANGULI, R., PANDINA, G., TURKOZ, I., BERRY, S., MAHMOUD, R., 2005, Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder, Journal of Clinical Psychiatry, 66, 2, 205-212.
- BUSHE, C., HADDAD, P., PEVELER, R., PENDLEBURY, J., 2005, The role of lifestyle interventions and weight management in schizophrenia. Journal of Psychopharmacology, 19, Suppl 6, 28-35.
- BUSTILLO, J. R., LAURIELLO, J., PARKER, K., HAMMOND, R., ROWLAND, L., BOGENSCHUTZ, M., KEITH, S., 2003, Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients, Neuropsychopharmacology, 28, 3, 527-529.
- CZOBOR, P., VOLAVKA, J., SHEITMAN, B., LINDENMAYER, J. P., CITROME, L., MCENVOY, J., LIEBERMAN, J. A., 2002, Antipsychotic-induced weight gain and therapeutic response : A differential association, Journal of Clinical Psychopharmacology, 22, 3, 244-251.
- DEBERDT, W., WINOKUR, A., CAVAZZONI, P. A., TRZASKOMA, Q. N., CARLSON, C. D., BYMASTER, F. P., WYENER, K., FLORIS, M., BREIER, A., 2005, Amantadine for weight gain associated with olanzapine treatment, European Neuropsychopharmacology, 15, 1, 13-21.
- DUBISAR, B. M., STONER, S. C., REYNOLDS, J., KHAN, R., RAMLATCHMAN, L., 2004, Adverse effects of atypical antipsychotic agents and their effects on quality of life, Pharmacotherapy, 24, 7, 843-847.
- EVANS, S., NEWTON, R., HIGGINS, S., 2005, Nutritional intervention to prevent weight gain in patients commenced on olanzapine : A randomized controlled trial, Australian and New Zealand Journal of Psychiatry, 39, 6, 479-486.
- FAGIOLINI, A., ROY CHENGAPPA, K., 2007, Weight gain and metabolic issues of medicines used for bipolar disorder, Current Psychiatry Reports, 9, n° 6, 521-528.
- FAGIOLINI, A., FRANK, E., SCOTT, J. A., TURKIN, S., KUPFER, D. J., 2005, Metabolic syndrome in bipolar disorder : Findings from the Bipolar Disorder Center for Pennsylvanians, Bipolar Disorders, 7, 5, 424-430.
- FAULKNER, G., COHN, T. A., 2006, Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications, Canadian Journal of Psychiatry, 51, 8, 502-511.
- FENTON, W. S., CHAVEZ, M. R., 2006, Medication-induced weight gain and dyslipidemia in patients with schizophrenia, The American Journal of Psychiatry, 163, 10, 1697-1704.
- GOLDSTEIN, D. J., 1992, Beneficial health effects of modest weight loss, International Journal of Obesity and Related Metabolic Disorders, 16, 6, 397-415.
- HAMMAN, R. F., WING, R. R., EDELSTEIN, S. L., LACHIN, J. M., BRAY, G. A., DELAHANTY, L., HOSKIN, M., KRISKA, A. M., MAYER-DAVIS, E. J., PI-SUNYER, X., REGENSTEINER, J., VENDITTI, B., WYLIE-ROSETT, J., 2006, Effect of weight loss with lifestyle intervention on risk of diabetes, Diabetes care, 29, 9, 2102-2107.
- HENDERSON, D. C., COPELAND, P. M., DALEY, T. B., BORBA, C. P., CATHER, C., NGUYEN, D. D., LOUIE, P. M., EVINS, E., FREUDENREICH, O., HAYDEN, D., GOFF, D. C., 2005, A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain, The American Journal of Psychiatry, 162, 5, 954-962.
- HESTER, E. K., THROWER, M. R., 2005, Current options in the management of olanzapine-associated weight gain, The Annals of Pharmacotherapy, 39, 2, 302-310.
- HOLT, R. A., MAUNDER, M. W., 1996, Is lithium-induced weight gain prevented by providing healthy eating advice at the commencement of lithium therapy ?, Journal of Human Nutrition & Dietetics, 9, 2, 127-133.
- IGLESIAS-GARCÍA, C., TOIMIL-IGLESIAS, A., ALONSO-VILLA, M. J., 2010, Pilot study of the efficacy of an educational programme to reduce weight, on overweight and obese patients with chronic stable schizophrenia, Journal of Psychiatric and Mental Health Nursing, 17, 9, 849-851.
- JEAN-BAPTISTE, M., TEK, C., LISKOV, E., CHAKUNTA, U. R., NICHOLLS, S., HASSAN, A. Q., BROWNELL, K. D., WEXLER, B. E., 2007, A pilot study of a weight management program with food provision in schizophrenia, Schizophrenia Research, 96, n° 1-3, 198-205.
- KHAZAAL, Y., FRESARD, E., RABIA, S., CHATTON, A., ROTHEN, S., POMINI, V., GRASSET, F., BORGEAT, F., ZULLINO, D., 2007, Cognitive behavioural therapy for weight gain associated with antipsychotic drugs, Schizophrenia Research, 91, 1-3, 169-177.
- KO, Y. H., JOE, S. H., JUNG, I. K., KIM, S. H., 2005, Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain, Clinical Neuropharmacology, 28, 4, 169-175.
- KURZTHALER, I., FLEISCHHACKER, W. W., 2001, The clinical implications of weight gain in schizophrenia, Journal of Clinical Psychiatry, 62, Suppl. 7, 32-37.
- KWON, J. S., CHOI, J. S., BAHK, W. M., KIM, C. Y., KIM, C. H., SHIN, Y. C., PARK, B. J., OH, C. G., 2006, Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder : A 12-Week randomized controlled clinical trial, Journal of Clinical Psychiatry, 67, 4, 547-553.
- LEUCHT, S., HERES, S., 2006, Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia, Journal of Clinical Psychiatry, 67, suppl 5, 3-8.
- LITTRELL, K. H., HILLIGOSS, N. M., KIRSHNER, C. D., PETTY, R. G., JOHNSON, C. G., 2003, The effects of an educational intervention on antipsychotic-induced weight gain, Journal of Nursing Scholarship, 35, 3, 237-241.
- MACMAHON, S., CUTLER, J., BRITTAIN, E., HIGGINS, M., 1987, Obesity and hypertension : Epidemiological and clinical issues, European Heart Journal, 8, suppl B, 57-70.
- MAURI, M., SIMONCINI, M., CASTROGIOVANNI, S., IOVIENO, N., CECCONI, D., DELL’AGNELLO, G., QUADRIGLI, M., ROSSI, A., DONDA, P., FAGIOLINI, A., CASSANO, G. B., 2008, A psychoeducational program for weight loss in patients who have experienced weight gain during antipsychotic treatment with olanzapine, Pharmacopsychiatry, 41, 1, 17-23.
- MCINTYRE, R. S., KONARSKI, J. Z., MISENER, V. L., KENNEDY, S. H., 2005, Bipolar disorder and diabetes mellitus : Epidemiology, etiology, and treatment implications, Annals of Clinical Psychiatry, 17, 2, 83-93.
- MELAMED, Y., STEIN-REISNER, O., GELKOPF, M., LEVI, G., SIVAN, T., LLIEVICI, G., ROSENBERG, R., WEIZMAN, A., BLEICH, A., 2008, Multi-modal weight control intervention for people with persistent mental disorders, Psychiatric Rehabilitation Journal, 31, 3, 194-200.
- MELTZER, H. Y., PERRY, E., JAYATHILAKE, K., 2003, Clozapine-induced weight gain predicts improvement in psychopathology, Schizophrenia Research, 59, 1, 19-27.
- MENZA, M., VREELAND, B., MINSKY, S., GARA, M., RADLER, D. R., SAKOWITZ, M., 2004, Managing atypical antipsychotic-associated weight gain : 12-month data on a multimodal weight control program, Journal of Clinical Psychiatry, 65, 4, 471-477.
- NEMEROFF, C. B., 2003, Safety of available agents used to treat bipolar disorder : Focus on weight gain, Journal of Clinical Psychiatry, 64, 5, 532-539.
- NEWCOMER, J. W., 2006, Medical risk in patients with bipolar disorder and schizophrenia, Journal of Clinical Psychiatry, 67, Suppl. 9, 25-30.
- NHLBI OBESITY EDUCATION INITIATIVE EXPERT PANEL ON THE IDENTIFICATION, EVALUATION AND TREATMENT OF OVERWEIGHT AND OBESITY IN ADULTS, 2000, The practical guide : Identification, evaluation, and treatment of overweight and obesity in adults : National heart, lung and blood institute, NIH Publication, 00, 4084, 1-83.
- NHLBI OBESITY EDUCATION INITIATIVE EXPERT PANEL ON THE IDENTIFICATION, EVALUATION AND TREATMENT OF OVERWEIGHT AND OBESITY IN ADULTS, 1998, Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults, NIH Publication, 98, 4083, 1-228.
- ORGANISATION MONDIALE DE LA SANTÉ, 2003, Obésité : Prévention et prise en charge de l’épidémie mondiale, OMS, Série de rapports techniques, 894, 1-300.
- PERKINS, D. O., 2002, Predictors of noncompliance in patients with schizophrenia, Journal of Clinical Psychiatry, 63, 12, 1121-1128.
- POULIN, M., CHAPUT, J., SIMARD, V., VINCENT, P., BERNIER, J., GAUTHIER, Y., LANCTÔT, G., SAINDON, J., VINCENT, A., GAGNON, S., TREMBLAY, A., 2007, Management of antipsychotic-induced weight gain : Prospective naturalistic study of the effectiveness of a supervised exercise programme, Australian and New Zealand Journal of Psychiatry, 41, 12, 980-989.
- POYUROVSKY, M., ISAACS, I., FUCHS, C., SCHNEIDMAN, M., FARAGIAN, S., WEIZMAN, R., WEIZMAN, A., 2003, Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia : A double-blind, placebo-controlled study, The American Journal of Psychiatry, 160, 2, 297-302.
- POYUROVSKY, M., PASHINIAN, A., GIL-AD, I., MAAYAN, R., SCHNEIDMAN, M., FUCHS, C., WEIZMAN, A., 2002, Olanzapine-induced weight gain in patients with first-episode schizophrenia : A double-blind, placebo-controlled study of fluoxetine, The American Journal of Psychiatry, 159, 6, 1058-1060.
- POYUROVSKY, M., TAL, V., MAAYAN, R., GIL-AD, I., FUCHS, C., WEIZMAN, A., 2004, The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients : A double-blind placebo-controlled pilot study, European Neuropsychopharmacology, 14, 4, 332-336.
- ROY CHENGAPPA, R., CHALASANI, L., BRAR, J. S., PAREPALLY, H., HOUCK, P., LEVINE, J., 2002, Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate : An open-label, nonrandomized chart review, Clinical Therapeutics : The International Peer-Reviewed Journal of Drug Therapy, 24, 10, 1576-1584.
- SCHWARTZ, T. L., NIHALANI, N., VIRK, S., JINDAL, S., CHILTON, M., 2004, Psychiatric medication-induced obesity : Treatment options, Obesity Reviews, 5, 4, 233-238.
- SCOTT, J., POPE, M., 2002, Self-reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalization, The American Journal of Psychiatry, 159, 11, 1927-1929.
- SEIDELL, J. C., 1998, Societal and personal costs of obesity, Experimental and Clinical Endocrinology and Diabetes, 106, Suppl. 2, 7-9.
- STONE, N. J., SAXON, D., 2005, Approach to treatment of the patient with metabolic syndrome : Lifestyle therapy, The American Journal of Cardiology, 96, 4, Suppl. 1, 15-21.
- THOMAS, P. R., 1995, Weighing the options : Criteria for evaluating weight-management programs, National Academies Press, Washington DC.
- UMBRICHT, D. S. G., POLLACK, S., KANE, J. M., 1994, Clozapine and weight gain, Journal of Clinical Psychiatry, 55, Suppl. B, 157-160.
- VREELAND, B., MINSKY, S., MENZA, M., RADLER RIGASSIO, D., ROEMHELD-HAMM, B., STERN, R., 2003, A program for managing weight gain associated with atypical antipsychotics, Psychiatric Services, 54, 8, 1155-1157.
- WEBER, M., WYNE, K., 2006, A cognitive/behavioral group intervention for weight loss in patients treated with atypical antipsychotics, Schizophrenia Research, 83, 1, 95-101.
- WEIDEN, P., RADULOVIC, L., WANG, C., ALLISON, D., 2003, Sibutramine for the treatment of obesity in schizophrenia : Randomized, placebo controlled pilot study, Paper presented at the American Psychiatric Association Annual Meeting, San Fransisco (CA).
- WILDES, J. E., MARCUS, M. D., FAGIOLINI, A., 2006, Obesity in patients with bipolar disorder : A biopsychosocial-behavioral model, Journal of Clinical Psychiatry, 67, 6, 904-915.
- WIRSHING, D. A., 2004, Schizophrenia and obesity : Impact of antipsychotic medications, Journal of Clinical Psychiatry, 65, Suppl. 18, 13-26.
- WU, R. R., ZHAO, J. P., JIN, H., SHAO, P., FANG, M. S., GUO, X. F., HE, Y. Q., LIU, Y. J., CHEN, J. D., LI, L.-H., 2008, Lifestyle intervention and metformin for the treatment of antipsychotic-induced weight gain : A randomized controlled trial, Journal of the American Medical Association, 299, 2, 185-193.
- ZIMMERMANN, U., KRAUS, T., HIMMERICH, H., SCHULD, A., POLLMÄCHER, T., 2003, Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients, Journal of Psychiatric Research, 37, 3, 193-220.